What are the specific efficacy and mechanisms of tucatinib?

Tucatinib, also known as tucatinib, is a new type of oral HER2-targeted drug. It is mainly used to treat HER2-positive breast cancer, especially in patients with brain metastasis or after failure of multiple lines of treatment. It has shown significant efficacy. The following are four aspects of tucatinib’s efficacy mechanism:

Highly selective inhibitionHER2 signaling pathway: Tucatinib is a highly selective small molecule tyrosine kinase inhibitor (TKI), mainly Acts on HER2 receptors and has little effect on HER1 (EGFR). This means that it can effectively inhibit HER2 signaling, block the proliferation and survival pathways of cancer cells, and at the same time avoid the side effects caused by EGFR inhibition, such as diarrhea and rash, improving drug tolerance.

Exerting a synergistic effect in combination with otherHER2 targeted drugs: tucatinib is usually combined with trastuzumab (Trastuzumab) and capecitabine (Capecitabine) are used in combination. This combination can achieve multiple HER2 pathway attacks. Trastuzumab acts on the extracellular structure of HER2, while tucatinib blocks intracellular signaling. The combination of the two greatly enhances the anti-tumor effect, especially against drug-resistant HER2-positive tumors.

It has the advantage of penetrating and curing brain metastases: A prominent feature of tucatinib is that it can penetrate the blood-brain barrier, which is an advantage that many HER2 targeted drugs do not have. In the treatment of HER2-positive breast cancer patients with brain metastases, tucatinib combination therapy significantly prolonged progression-free survival and overall survival, showing good central nervous system control.

Delay disease progression and improve survival: In clinical studiesHER2CLIMB, tucatinib significantly prolonged the median progression-free survival (PFS) and overall survival (OS) of patients. Its mechanism of action is through sustained inhibitionHER2 signal activation slows down tumor proliferation and metastasis, bringing patients longer survival time and better quality of life, especially for patients with advanced breast cancer whose disease is still progressing after multiple lines of treatment.

Reference materials:https://www.drugs.com/